A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab-bevacizumab to avoid graft rejection?
- PMID: 35396831
- DOI: 10.1002/lt.26475
A standardized immunosuppressive regimen for patients who received liver transplantations treated with atezolizumab-bevacizumab to avoid graft rejection?
Comment on
-
Preliminary Evaluation of Atezolizumab Plus Bevacizumab as Salvage Treatment for Recurrent Hepatocellular Carcinoma After Liver Transplantation.Liver Transpl. 2022 May;28(5):895-896. doi: 10.1002/lt.26416. Epub 2022 Feb 24. Liver Transpl. 2022. PMID: 35090081 No abstract available.
References
-
- Yang Z, Sun J, Zhuang L, Mou H, Zheng S. Preliminary evaluation of atezolizumab plus bevacizumab as salvage treatment for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2022;28:895–6.
-
- Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T‐Y, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
-
- Nguyen LS, Ortuno S, Lebrun‐Vignes B, Johnson DB, Moslehi JJ, Hertig A, et al. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review. Eur J Cancer. 2021;148:36–4.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical